Last updated: 2026-09-21 21:44:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Equillium, Inc. (EQ) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,89, with a market capitalization of $121,74M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,76 to $3,54. This page covers its latest market performance, valuation, price trends and company information.
$121,74M | |
$1,98 | |
$65,50 | |
$0,27 | |
$1,92 | |
250,71K | |
643,98K | |
-- | |
$3,54 | |
$0,76 | |
-- | |
-- |
Equillium, Inc. (EQ) is trading at $1,90 in after-hours trading as of 2026-09-21 20:52:00, down 1,30% ($0,02) from the regular-session close of $1,92.
After-hours trading shows how investors are pricing EQ after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Equillium, Inc. (EQ) moved from $2,42 to $1,89, representing a decline of 21,94% ($0,53).
The stock traded between $1,80 and $2,69 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 539,55 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 40,7%
EQ is currently trading at $1,89, placing it 40,7% of the way from its 52-week low of $0,76 to its 52-week high of $3,54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 14 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Equillium, Inc. (EQ) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.